Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of autism spectrum disorder (ASD) and a variety of symptoms related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.

Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of Alzheimer's disease (AD) and a variety of symptoms related thereto with amino sterols or pharmaceutically acceptable salts or derivatives thereof.

Abstract: This invention relates to methods of treating constipation and constipation-related symptoms in a subject in need. The methods, which utilize a patient-specific “fixed dose” of an aminosterol, comprise administering a therapeutically effective dose of an aminosterol to a subject in need.

Abstract: The present application relates generally to compositions and methods for treating, preventing, and/or slowing the onset or progression of cardiac conduction defects (CCDs) and a variety of symptoms related thereto with amino sterols or pharmaceutically acceptable salts or derivatives thereof.

Abstract: The present application relates generally to methods for treating, preventing, and/or slowing the onset or progression of depression and a variety of symptoms related thereto with aminosterols or pharmaceutically acceptable salts or derivatives thereof.

Abstract: This invention relates to methods of treating and/or preventing the progression and/or onset of age-related neurodegeneration. The invention also relates to methods of reversibly slowing the growth and/or aging of a subject, and/or extending the potential lifespan of the subject, comprising administration of the naturally occurring aminosterol MSI-1436, or derivatives or salts thereof. Also described are methods of treating, preventing or delaying the onset of age-related diseases or conditions comprising administration of Aminosterol 1436, or derivatives or salts thereof.

Abstract: This application relates to methods of treating, preventing and/or slowing the onset or progression of hallucinations and/or related symptoms caused by a variety disorders, with aminosterols or pharmaceutically acceptable salts or derivatives thereof.

Abstract: Provided herein are crystalline solid forms of squalamine phosphate designated as Form 1 and Form 2, compositions containing one or both forms, and methods of their preparation and of their use.

Abstract: This invention relates to methods of treating or preventing a sleep disorder, sleep disturbance, or related symptom in a subject with aminosterols or pharmaceutically acceptable salts or derivatives thereof. In particular, the disclosed methods generally comprise administering an aminosterol to a subject in need, thereby stimulating an aminosterol-induced CNS response to treat and/or prevent a sleep disorder, sleep disturbance, or related symptom.

Abstract: Described are methods of treating or preventing an inflammatory disease or condition caused by excessive expression, secretion, or concentration of alpha synuclein. The methods comprise administering compositions that reduce the effective concentration of alpha-synuclein present in the surrounding tissues. In addition, the invention encompasses methods of inhibiting alpha-synuclein interaction with CD11b, comprising administering an agent that binds to alpha-synuclein to prevent binding productively to the integrin CD11b, or administering an active agent that interacts with CD11b on an immune cell to prevent alpha-synuclein from directing chemotaxis of that cell. In addition, the invention discloses a method of identifying an individual with a condition amenable to treatment targeting alpha-synuclein CD11b interaction.

Abstract: Methods for cerebral cooling are described. Cooling assemblies include elongate tubular members, a reservoir containing a pressurized fluid, and a manifold connecting the reservoir and elongate tubular members. After insertion of the elongate tubular members into the patient's nostrils, a pressurized fluid is delivered onto a surface of the patient's nasal cavity through a plurality of ports in the elongate tubular members. The delivery of the fluid causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis.

Abstract: Devices for cerebral and systemic cooling via a patient's nasopharyngeal cavity are described. Cooling assemblies include at least one elongate tubular member having first and second lumens, a source of liquid coolant, a gas source communicating with the first lumen, and a switch for alternately connecting the liquid coolant source to the second lumen. The first lumen transports a compressed gas and the second lumen transports a volatile liquid. The pressurized fluid may be a perflurocarbon. The perfluorocarbon may be perfluorohexane, perfluoropentane, or 2-methyl-perfluoropentane. The gas may be air, oxygen, or a combination.

Abstract: Methods for cerebral and systemic cooling via a patient's nasopharyngeal cavity are described. In one method, a cooling assembly is inserted into a nasal cavity through a patient's nostril. A substantially dry gas is delivered through a lumen of the catheter onto the surface of the patient's nasal cavity. Evaporative heat loss cools the patient's nasal cavity. If additional cooling is needed, a liquid coolant is delivered through a separated lumen of the catheter. The liquid coolant is nebulized at a plurality of delivery ports on the distal end of the catheter and is delivered onto the surface of the patient's nasal cavity in combination with the dry gas. The dry gas enhances evaporation of the nebulized coolant and additional cooling is provided from the evaporative heat loss of the liquid coolant.

Abstract: A system for improving outcome following cerebral ischemia is provided. The system includes a source of nitric oxide and an elongate tubular member for insertion into a nose including at least one orifice thereon. The elongate tubular member is coupled to the source of nitric oxide and configured for delivering the nitric oxide into a nasal cavity through the at least one orifice for absorption into a cerebral vasculature through a nasal vasculature. A device for controlling flow of the gas, a concentration of the nitric oxide in the gas, or both, is also provided.

Abstract: A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist.

Abstract: Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg.

Abstract: Methods for cerebral cooling are described. Cooling assemblies include elongate tubular members, a reservoir containing a pressurized fluid, and a manifold connecting the reservoir and elongate tubular members. After insertion of the elongate tubular members into the patient's nostrils, a pressurized fluid is delivered onto a surface of the patient's nasal cavity through a plurality of ports in the elongate tubular members. The delivery of the fluid causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis.

Abstract: Devices and methods for filtering blood. The devices generally comprise a mesh for filtering blood flowing within a blood vessel, particularly within an artery such as the aorta, a structure adapted to open and close the mesh within the blood vessel, and a device or method to actuate the structure. The methods generally include the steps of introducing a mesh into a blood vessel to entrap emboli material, and removing the mesh and the entrapped foreign matter from the blood vessel.

Abstract: A method for providing and adjusting cerebral cooling in response to changes in a physiological parameter. A spray having a boiling point between 38-300° C. is delivered to the surface of a patient's nasal cavities. The spray causes cooling by direct heat transfer through the nasopharynx and hematogenous cooling through the carotids and the Circle of Willis. A physiological parameter, such as cerebral temperature, changes in cerebral blood flow or brain oxygenation is monitored. The delivery rate of the spray is adjusted in response to the physiological parameter.

Abstract: A method of modulating a physiological parameter of a patient is provided. The method includes disabling one or more pre-aortic ganglion cells within a pre-aortic ganglion and improving the physiological parameter. The method further includes destroying a pre-aortic ganglion cell to prevent regeneration.